Life sciences

Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Life sciences, DNA sequencing, Molecular biology, Biotechnology, Pacific Biosciences, DNA, Bioinformatics, Third-generation sequencing, Read, DNA sequencer

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.

Key Points: 
  • MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.
  • Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type.
  • High quality, long-read sequencing begins with high quality, long DNA.
  • Circulomics Nanobind magnetic disks protect DNA from shearing to generate long reads across a broad range of sample types.

Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company August 3, 2021 as its new Chief Medical Officer.

Key Points: 
  • AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company August 3, 2021 as its new Chief Medical Officer.
  • I am thrilled to welcome noted endocrinologist and industry veteran, Dr. David B. Karpf, as our new Chief Medical Officer, commented Rick Hawkins, Chairman and CEO of Lumos Pharma.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.
  • This press release contains forward-looking statements of Lumos Pharma, Inc. (the Company) that involve substantial risks and uncertainties.

Pliant Therapeutics to Participate in the BTIG Biotechnology Conference

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology, Industry economics)

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 10, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 10, 2021.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter , LinkedIn , Facebook and YouTube .

Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-C

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology, Articles, Pharmaceutical industry, Sorrento, Biopharmaceutical

Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.

Key Points: 
  • Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.
  • Sorrento provides its most comprehensive portfolios and a one-stop-shop" of potential solutions for governments interested in a multi-modal detect and treat approach to the COVID-19 pandemic.
  • Sorrento Mexico plans to establish a local research laboratory within INMEGENs facilities to ensure close collaboration between the INMEGEN and Sorrento teams for testing, clinical trials and development of COVID related products.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Aurora Spine Corporation Announces FDA 510(k) Clearance for DEXA-C™ Cervical Interbody System

Retrieved on: 
Tuesday, August 3, 2021
Prosthetics, Medicine, Spine, Implant, Minimally invasive procedure, Forward-looking statement, Health sciences, Life sciences

Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, "This approval is the first of its kind in the world by offering an implant based upon a patient's bone density.

Key Points: 
  • Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, "This approval is the first of its kind in the world by offering an implant based upon a patient's bone density.
  • Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
  • Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release.
  • These statements speak only as of the date of this press release, and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

HTG Molecular Diagnostics to Announce Second Quarter 2021 Financial Results and Host Conference Call on Thursday, August 12

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Medical genetics, GlobeNewswire, Nasdaq, Inc., Precision medicine, Tucson, Arizona, NASDAQ, Biology, Molecular diagnostics, Life sciences

TUCSON, Ariz., Aug. 03, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on Thursday, August 12, 2021.

Key Points: 
  • TUCSON, Ariz., Aug. 03, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on Thursday, August 12, 2021.
  • Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm ET.

Pharmaceutics International, Inc. (Pii) to Platform West Pharmaceutical Services, Inc.’s Daikyo Crystal Zenith® Container-Closure Components for Aseptic Fill-Finish

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry, Health sciences, Life sciences, Syringe, Fill and finish, Contract manufacturing organization, Health care

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.

Key Points: 
  • Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.
  • Piis initial implementation will be filling ready-to-use (RU) syringes and cartridges in its aseptic fill-finish processes.
  • We are a trusted partner to the worlds top pharmaceutical and biotechnology companiesworking by their side to improve patient health.
  • Crystal Zenith technology is licensed to West Pharmaceutical Services, Inc. from Daikyo Seiko, Ltd.

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Stars, Companies, Life sciences, AstraZeneca, Medical research, Södertälje Municipality, Oxford–AstraZeneca COVID-19 vaccine, Wedbush Securities, Albireo, NASDAQ

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at3:30 p.m.

Key Points: 
  • BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at3:30 p.m.
  • The live webcast of the presentation will be accessible from the Media & Investors page of Albireos website, ir.albireopharma.com .
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU Langone Health

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Genomics, DNA, DNA sequencing, Genetic mapping, Molecular biology, Oncology

This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.

Key Points: 
  • This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.
  • The number of genes cancer types assayed is the largest among academic genomic sequencing tests of its kind.
  • Philips Genomics Workspace, hosted on cloud-based Philips HealthSuite, will help facilitate the integration into the EMR so tests can be seamlessly ordered, reviewed, and shared by a patients care team.
  • With Philips Genomics Workspace, oncologists can map a patients uniquecharacteristics to a therapy that is best suited for them and provide evidence on why that therapy is preferable.

Epizyme Announces Date of Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Biotechnology, Articles, Economy of New York City, NASDAQ, Biopharmaceutical

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m.

Key Points: 
  • Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m.
  • To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 3658407.
  • By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them.
  • TAZVERIK is a registered trademark of Epizyme, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210803006035/en/